Fintel reports that on January 23, 2025, Barclays downgraded their outlook for Galapagos NV - Depositary Receipt () (NasdaqGS:GLPG) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 48 ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Barclays downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of EUR 22, down from EUR 30. With Galapagos’ ongoing ...

Galapagos NV has a twelve month low of $23.45 and a twelve month high of $40.34. The business’s 50-day moving average price is $26.55 and its two-hundred day moving average price is $27.41 ...

Galapagos NV (NASDAQ:GLPG) is under modest pressure premarket, down 6% on increased volume on the heels of promising results from Vertex Pharmaceuticals' (NASDAQ:VRTX) triple... BySeeking Alpha ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Galapagos NV is a clinical-stage biotechnology company. It is engaged in the discovery and development of small molecule medicines which address unmet medical conditions.

In fact, the region is home to 45 types of marine birds and 22 land birds you won't see anywhere else (think: Galapagos penguins and Darwin's finches), not to mention other unique species like ...